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Abstract
The benzothiazinone lead compound, BTZ043, kills Mycobacterium
tuberculosis by inhibiting the essential flavo-enzyme DprE1, deca-
prenylphosphoryl-beta-D-ribose 2-epimerase. Here, we synthesized
a new series of piperazine-containing benzothiazinones (PBTZ) and
show that, like BTZ043, the preclinical candidate PBTZ169 binds
covalently to DprE1. The crystal structure of the DprE1-PBTZ169
complex reveals formation of a semimercaptal adduct with Cys387
in the active site and explains the irreversible inactivation of the
enzyme. Compared to BTZ043, PBTZ169 has improved potency,
safety and efficacy in zebrafish and mouse models of tuberculosis
(TB). When combined with other TB drugs, PBTZ169 showed addi-
tive activity against M. tuberculosis in vitro except with bedaquiline
(BDQ) where synergy was observed. A new regimen comprising
PBTZ169, BDQ and pyrazinamide was found to be more efficacious
than the standard three drug treatment in a murine model of
chronic disease. PBTZ169 is thus an attractive drug candidate to
treat TB in humans.
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Introduction
Today, tuberculosis (TB) accounts for the annual loss of approxi-
mately 1.5 million lives worldwide and the pandemic is exacer-
bated by poverty, homelessness, synergy with HIV/AIDS and
widespread drug resistance (WHO, 2012). While most of the 9
million new TB cases occur in the developing world, the industri-
alized nations, especially in Europe, are also at increasing risk
due to the inexorable spread of drug-resistant disease through
global travel and immigration. There are an estimated 650 000
cases of multidrug-resistant TB (MDR-TB), which no longer
respond to frontline treatment, and in excess of 60 000 cases of
extensively drug-resistant TB (XDR-TB), that are resistant to key
second-line drugs in addition, among the world’s 12 million
prevalent cases of TB (WHO, 2012). Around 2 billion individuals
have latent TB and MDR-TB is currently threatening the success
of both the TB and HIV control programs worldwide.
The past decade has seen intensive efforts to discover and
develop new drugs to treat drug-susceptible-, MDR- and XDR-TB,
and new combination regimens are also being devised and tested
in clinical trials (Koul et al, 2011; Diacon et al, 2012). New regi-
mens will most likely employ a combination of repurposed drugs
and new chemical entities (NCE) and there is a real likelihood
that these regimens may contain none of the drugs previously
used in TB treatment (Zumla et al, 2013). Repurposed drugs
include members of the fluoroquinolone, oxazolidinone, rimino-
phenazine and rifamycin families. Among the most advanced NCE
in phase II and phase III clinical trials are the diarylquinoline,
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bedaquiline or BDQ (Andries et al, 2005; Diacon et al, 2009); the
bicyclic nitroimidazoles, PA-824 (Stover et al, 2000; Diacon et al,
2012), delamanid or OPC67683 (Matsumoto et al, 2006; Gler,
2012); and SQ109, a novel 1,2-ethylenediamine-based analogue
(Lee et al, 2003; Tahlan et al, 2012).
The current TB drug development pipeline also has extensive
activity in the early stages (Zumla et al, 2013), but there is a
gap, corresponding to late preclinical development and phase I
clinical trials, that needs filling to ensure continuity of clinical
activity and to compensate for the probable attrition among the
more advanced candidates. One NCE that is nearing phase I clini-
cal trials is the benzothiazinone, BTZ043 (2-[(2S)-2-methyl-1,4-
dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-ben-
zothia-zin-4-one). BTZ043 is one of the most potent inhibitors of
Mycobacterium tuberculosis yet described, displaying nanomolar
bactericidal activity both in vitro and in ex vivo models of TB
(Makarov et al, 2009). In murine models of acute and chronic
TB, BTZ043 showed efficacy approaching that observed with the
frontline drugs isoniazid and rifampin although these are far less
potent with respect to their in vitro minimal inhibitory concentra-
tions (MIC).
BTZ043 (Fig 1), a nitroaromatic compound, is active against
MDR-clinical isolates of M. tuberculosis (Makarov et al, 2009; Pasca
et al, 2010) and targets the essential flavoprotein subunit, DprE1, of
decaprenylphosphoryl-beta-D-ribose 2-epimerase. This enzyme pro-
duces the sole source of the D-arabinose required for biosynthesis of
the key cell wall components arabinogalactan and lipoarabinoman-
nan. BTZ043 serves as a suicide substrate for the reduced form of
DprE1 undergoing nitroreduction to yield a nitroso species that spe-
cifically attacks the thiol side chain of the active site cysteine resi-
due, Cys387, thereby forming a covalent adduct and irreversibly
inactivating the enzyme (Trefzer et al, 2010, 2012; Neres et al,
2012).
Since the efficacy of BTZ043 in the mouse model of TB was
lower than expected from its exceptional potency (MIC - 1 ng/ml;
2.3 nM) and the compound is relatively hydrophobic (logP = 2.84)
we suspected that the pharmacologic properties could be improved.
Consequently, we have produced a new, enhanced series of benzo-
thiazinones, the PBTZ, by introducing a piperazine group into the
scaffold. Here, we present the findings of a comparison of the next-
generation preclinical candidate PBTZ169 (Fig 1) with BTZ043, and
describe its superior properties and suitability for inclusion in a new
combination regimen for the treatment of both drug-susceptible and
drug-resistant TB.
Results
SAR studies of piperazine-containing benzothiazinone
derivatives
During our structure-activity relationship (SAR) analysis of the first
generation benzothiazinone (BTZ) compounds we discovered a
direct correlation between lipophilicity (logP) and antimycobacterial
activity (Makarov et al, 2009). The aim of the present research was
to design and synthesize a new generation of BTZ derivatives, that
were sufficiently lipophilic to be highly antimycobacterial but with
better pharmacodynamic parameters to increase their in vivo effi-
cacy. Based on our prior knowledge of the BTZ scaffold, with its great
affinity for DprE1, it was clear that even minor structural changes led
to loss of antimicrobial activity. For instance, key constituents are the
sulfur and oxygen atoms in the thiazine ring, strong electron acceptor
groups (CF3, CN, NO2 etc.) in position 6, and protons in positions 5
and 7 (Fig 1). The essentiality of the nitro group in position 8 was
demonstrated by synthesizing and characterizing many benzothiazi-
none derivatives with alternative electron withdrawing groups in that
position, but these were all inactive (Makarov et al, 2009). An expla-
nation for this was provided when the mechanism of action was elu-
cidated and the structure of the BTZ043-DprE1 complex was solved
(Trefzer et al, 2010, 2012; Neres et al, 2012).
Based on our previous studies, only position 2 of the BTZ scaffold
remained for derivatization. We designed a new series of substituted
2-piperazino-benzothiazinones (PBTZs), which allowed extensive
SAR studies through variation of the piperazine N-4 substituents,
which were rapidly synthesized from the parent substituted pipera-
zines. From the SAR studies performed, it soon became evident that
hydrophilic groups including alcohols, carboxylic acids and second-
ary or tertiary amines invariably led to loss of antimycobacterial
activity when compared to BTZ043 (Supplementary Table 1).
A second family of compounds, with more hydrophobic substitu-
ents on the piperazine ring was then synthesized. In this case, the
small hydrophilic and saturated piperazine moiety is “hidden”
between two hydrophobic groups: the crucial 1,3-benzothiazin-
4-one ring and the N-4 piperazino substituent. A series of aryl-
PBTZs, containing substituted phenyl rings or pyridyl moieties was
synthesized and found to have low in vitro and in vivo activity (Sup-
plementary Table 1). Finally, a series of alkyl-PBTZs was synthe-
sized, which had the advantages of improving the aqueous
solubility of the resulting compounds through protonation of the ter-
tiary amino nitrogen of the piperazine ring, and the fact that the
Figure 1. Chemical structures. Structure of BTZ043
and five compounds of the PBTZ family selected for in vivo
studies, PBTZ169, PBTZ139, PBTZ134, PBTZ137 and
PBTZ139.
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hydrophobicity of the molecule could be readily modulated through
introduction of various alkyl groups (Table 1 and Supplementary
Table 1). Details of the general synthetic route may be found in the
supporting information and elsewhere (Makarov, 2011).
The in vitro activities against M. tuberculosis H37Rv of the 60
resultant PBTZ compounds were measured by the resazurin reduc-
tion microplate assay (REMA). The alkyl-PBTZ series of compounds
showed the most potent anti-tuberculosis activity and displayed a
strong correlation between MIC and lipophilicity (Table 1 and Sup-
plementary Table 1), based on their respective calculated logPs.
Selected PBTZ compounds displaying MICs ranging from 0.19 to
0.75 ng/ml against M. tuberculosis H37Rv were tested in their free
base and hydrochloride salt forms but the MIC values obtained were
identical. The in vivo efficacy of a range of PBTZ derivatives
(PBTZ169, 129, 134, 137, 139) was then tested in the chronic TB
mouse model and the results are presented below. The most attrac-
tive compound was PBTZ169, which appears more stable than the
other derivatives synthesized probably because its cyclohexyl group
protects against enzymatic attack by nitroreductases and the
methylene linker is sandwiched between two bulky groups.
Microbiological characterization of PBTZ169 and selected
derivatives
The MIC99 of PBTZ169 and BTZ043 were determined for a variety of
actinobacteria by REMA. Two TB drugs, moxifloxicin (MXF) and
rifampicin (RIF) were used for control purposes. PBTZ169 was
found to be three- to seven-fold more active than BTZ043 against
M. tuberculosis, Mycobacterium bovis BCG,Mycobacterium marinum,
Mycobacterium smegmatis, Corynebacterium diphtheriae and Cory-
nebacterium glutamicum (Table 2). PBTZ169 and BTZ043 were not
active against atypical mycobacteria like M. avium (Makarov et al,
2009) nor against M. abscessus, M. boletti, M. massiliense and
M. vaccae (Table 2) probably because these mycobacteria possess
dprE1 genes where the codon equivalent to Cys387 of M. tuberculo-
sis has been replaced by an Ala or Ser codon (see below). Consistent
with previous findings (Makarov et al, 2009; Pasca et al, 2010),
both PBTZ169 and BTZ043 were active against MDR- and XDR-clini-
cal isolates of M. tuberculosis (Table 2 and Supplementary Table 2).
To establish whether cross-resistance, indicative of a common
target, was observed between BTZ043 and PBTZ169 we tested two






10926013 Methyl 250 1.31
10926021 Ethyl 62 1.64
10926027 Propyl 3.7 2.11
10926172 Butyl 1.9 2.51
11026100 Isobutyl 1.9 2.51
11026142 1-Ethylpropyl 0.37 2.99
11026128 1-sec-Butyl 0.37 2.52
11026129, PBTZ129 2-Cyclohexylethyl 0.19 3.52
11026131 1-Methylbutyl 0.19 3.11
11026134, PBTZ134 Heptyl 0.19 3.30
11026137, PBTZ137 4-Phenoxybutyl 1.5 3.35
11026139, PBTZ139 4-Phenylbutyl 0.37 4.05
10926168 Cyclohexyl 0.75 3.09
10926169, PBTZ169 Cyclohexylmethyl ≤0.19 3.20
*Calculated using Hyperchem 7.5 (Hypercube Inc., http://www.hyper.com).
Table 2. MIC determinations for different Actinobacteria by REMA
MIC99 (lg/ml)
BTZ043 PBTZ169 RIF MXF
C. diphtheriae DSM 44123 0.06 0.003 0.0008 0.02
C. glutamicum ATCC 13032 0.063 0.013 0.004 0.31
M. abscessus 2005-0524 >100 >100 6.25 0.78
M. avium ATCC 15769 >100 >100 25 0.47
M. bolletii 1999-0888 >100 >100 50 0.94
M. bovis BCG Pasteur 0.001 0.0006 0.001 0.02
M. bovis BCG BN2 >100 >100 0.0008 0.03
M. marinum Strain M 0.0007 0.0003 0.39 0.1
M. massiliense 2005-0484 >100 >100 25 0.96
M. smegmatis mc2155 0.001 0.0007 0.5 0.06
M. smegmatis GM22 0.031 0.003 1 0.06
M. smegmatis MN47 25 6.25 1 0.06
M. smegmatis MN84 >100 >100 1 0.06
M. tuberculosis H37Rv 0.001 0.0003 0.001 0.03
M. tuberculosis NTB1 25 >100 0.001 0.03
M. tuberculosis MDR_CHUV 0.002 0.0004 >100 0.03
M. vaccae ATCC 15483 >100 >100 100 0.63
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BTZ-resistant mutants, both with Cys387Ser missense mutations in
DprE1, namely, M. tuberculosis NTB1 and M. bovis BCG BN2, and
the drug-susceptible parent strains. The mutations conferred
>10 000-fold increased resistance to both compounds (Table 2). The
activities of BTZ043 and PBTZ169 were also compared against three
BTZ-resistant mutants of M. smegmatis, two of which harbor
missense mutations in DprE1 (MN47 Cys394Gly; MN84 Cys394Ser)
(Makarov et al, 2009) whereas the third overproduces the NfnB
nitroreductase (GM22) (Manina et al, 2010) that confers partial resis-
tance by inactivating BTZ043. Again the DprE1 mutants displayed
cross-resistance to both compounds, but PBTZ169 proved to be far
less susceptible than BTZ043 to inactivation by NfnB since their MICs
for GM22 were 5 and 50 ng/ml, respectively (Supplementary Fig 1).
Effect of nitroreduction by NfnB on PBTZ169 and selected
derivatives
To confirm that PBTZ169 was indeed more resistant than BTZ043
to nitroreduction by NfnB, both compounds were incubated with
purified recombinant M. smegmatis NfnB, as described previously
(Manina et al, 2010), and samples taken periodically for LC-MS
analysis. BTZ043 was reduced very quickly and after 30 min had
been almost entirely converted to its hydroxylamino analogue and a
trace amount of the nitroso intermediate (Fig 2). After 3 h incuba-
tion with NfnB, a new species was present with a molecular weight
of 814, observed in the LC-MS trace in its doubly-protonated form
(m/z = 433). This likely corresponds to the azoxy adduct formed
from two nitroso-BTZ043 molecules, as suggested by Tiwari et al
(Tiwari et al, 2013).
The fate of PBTZ169 on incubation with NfnB was quite different
from that of BTZ043, as even after 3 h incubation, the major species
found in the LC-MS analysis was the original nitro form. As
observed with BTZ043, the hydroxylamino and azoxy adducts of
PBTZ169 were also present in the assay mixture, but in much
smaller amounts. Similar results (data not shown) were obtained for
PBTZ129, PBTZ137 and PBTZ139 (Table 1). However, one of the
PBTZs tested, PBTZ134, was as susceptible to NfnB-mediated
reduction as BTZ043.
Figure 2. NfnB-mediated reduction of BTZ043 and PBTZ169. Compounds (50 lM) were incubated with NfnB (6 lM) as described in Materials and Methods. Samples
(10 lL) were taken at different times during the reaction and directly analyzed by LC-MS (ESI+). Results were analyzed by extracting the ion counts for the species of interest
for each compound, namely the protonated forms of the original compound, and its nitroso, hydroxylamino and amino forms, as well as the azoxy adducts.
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Enzymology: DprE1 inhibition in vitro
Inhibition of M. tuberculosis DprE1 by PBTZ169 and BTZ043 was
monitored by determining the residual enzyme activity following
incubation with a range of concentrations of these compounds,
using a two step coupled enzyme assay (Neres et al, 2012). For this
purpose, we expressed and purified M. tuberculosis DprE1 (Batt
et al, 2012). The results showed that full inhibition of DprE1 was
obtained following 5 min incubation with 5 lM PBTZ169 whereas
20 lM BTZ043 was required to achieve this (Supplementary Fig
2A). To confirm that PBTZ169 and BTZ043 shared the same mecha-
nism for DprE1 inhibition, namely the formation of a covalent
adduct with the active site cysteine, we incubated DprE1 with
PBTZ169 in the presence of the FPR (farnesylphosphoryl-ß-D-
ribofuranose) substrate. Mass spectrometry analysis of the protein
in the reaction mixture clearly showed that the expected semimer-
captal adduct was formed between PBTZ169 and DprE1 (Supple-
mentary Fig 2B) (Trefzer et al, 2010, 2012; Neres et al, 2012).
Crystal structure of the DprE1-PBTZ169 adduct
The structural and mechanistic similarities between BTZ043 and
PBTZ169 pointed to similar modes of binding to the active site of
DprE1 so, to fully characterize this, we determined the crystal
structure of the M. tuberculosis DprE1-PBTZ169 adduct using the
procedure previously reported for the M. smegmatis DprE1-
BTZ043 structure (Neres et al, 2012). DprE1-PBTZ169 crystals dif-
fracted to 1.9 A˚ resolution (Supplementary Table 3). The structure
(PDB 4NCR) was solved by molecular replacement using the
native M. tuberculosis DprE1 structure (PDB 4FDP (Batt et al,
2012)) as a model. The overall fold of the M. tuberculosis and
M. smegmatis DprE1 enzymes, and the position of the benzothi-
azinones in the respective active sites are very similar, as shown
in Fig 3A.
Closer inspection of the active site of the DprE1-PBTZ169 struc-
ture (Fig 3B) shows that the benzothiazinone ring interacts with the
same residues in the active site as previously observed in the
M. smegmatis DprE1-BTZ043 structure. The electron density map
does not account fully for the cyclohexyl moiety of PBTZ169
(Supplementary Fig 3A), likely due to its higher flexibility. The
cyclohexylmethyl-piperazine moiety is placed between the FAD fla-
vin ring and residues Gly117, Trp230 and Leu363 (Fig 3B), with the
side chains of the latter two adopting slightly different conforma-
tions when compared with the DprE1-BTZ043 complex structure. A
water molecule bridges a hydrogen bond between the carbonyl
oxygen of the BTZ ring and the backbone carbonyl of Leu115. Inter-
estingly, after modelling in the PBTZ169 structure and refinement,
extra electron density was observed in a pocket lined by PBTZ169
itself and the residues Trp111, Lys134, Phe199, amino acids
226-230, Phe313 and Tyr314. Given its proximity to the active site,
and the narrow elongated shape, we hypothesized that this
corresponded to bound FPX (farnesylphosphoryl-D-2-keto-erythro-
pentose), the product obtained by DprE1 oxidizing FPR. We mod-
elled the FPX structure in the mentioned electron density
(Supplementary Fig 3B), and verified that except for its sugar moi-
ety, placed in a free region between residues Trp230 and Gln308
with high B factors and essentially no electron density, the phos-
phate and farnesyl moieties fitted quite well. Therefore, it is highly
likely that the polyprenyl chain of the DprE1 substrate is located
adjacent to the BTZ binding site.
In vitro ADME/T characterization
The potential cytotoxicity of BTZ043 and PBTZ169 was assessed
using the HepG2 human cell line (Supplementary Table 4). PBTZ169
was found to be 10-times less cytotoxic (TD50 of 58 lg/ml) com-
pared to BTZ043 (TD50 of 5 lg/ml). Both compounds thus have
excellent selectivity indices of >10 000. On incubation with human
or mouse microsomes, both BTZ043 and PBTZ169 showed medium
clearance values (Supplementary Table 4).
A
B
Figure 3. Crystal structure of the M. tuberculosis DprE1-PBTZ169
complex.
A Cartoon representation of the M. tuberculosis DprE1 structure (grey) in
complex with PBTZ169 adduct (green sticks), and its FAD cofactor (yellow
sticks), superposed on the M. smegmatis DprE1 structure (blue) in complex
with BTZ043 and FAD. The location of the disordered regions in the
M. tuberculosis DprE1 are marked as black dashed lines. Residue numbers
are indicated in black for the M. tuberculosis structure and in blue for the
M. smegmatis protein.
B Close-up view of the M. tuberculosis DprE1 active site showing the
residues in close contact with PBTZ169. The binding pocket of the CF3
group of PBTZ169 is shown as a surface representation.
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Efficacy of PBTZ169 against M. marinum in zebrafish
To establish whether BTZ derivatives have the potential to cure
other mycobacterial infections we tested their efficacy against
M. marinum using the zebrafish embryo model as this has proved
to be a powerful tool for assessing the effect of TB drugs (Davis
et al, 2002; Adams et al, 2011). This model assesses simultaneously
the effect of compounds on host survival, host pathology and bacte-
rial burden. Embryos were infected with M. marinum strains E11 or
M, producing the fluorescent protein mCherry, and observed by flu-
orescence microscopy. Treatment of infected zebrafish embryos
with increasing concentrations of PBTZ169 or BTZ043 led to a
decrease in the bacterial burden after 5 days, as measured by the
amount of fluorescent pixels present in the embryos (Fig 4A).
Whereas infection with M. marinum M (or E11 data not shown)
resulted in substantial bacterial clustering (Fig 4B, C), almost no
bacteria were present when infected zebrafish embryos were treated
with 25 or 50 nM PBTZ169 or BTZ043 (Fig 4D, E, F). Treatment of
embryos with either compound at 5 nM had no significant effect on
the infection (Fig 4A, C).
To confirm the bactericidal effect, zebrafish embryos were
infected with M. marinum strains M and E11, and then exposed to
25 nM PBTZ169 for 5, 4 or 3 days with the drug added at 0, 1 or 2
days post-infection, respectively. The number of colony forming
units (CFU) per embryo was determined and compared to the level
of fluorescence. A decrease of about 3 and 2 log units was observed
in the number of CFU for the M. marinum strains M and E11,
respectively (Fig 5B, D) independently of the duration of treatment.
Decreasing bacterial viability was mirrored by a sharp decrease in
fluorescence although more scatter was seen at later time-points
(Fig 5A, C).
On examination of infected zebrafish embryos treated with
BTZ043 it was observed that the compound affected embryo
development (Fig 6A–G) especially at concentrations above
25 nM. Administration of BTZ043 to the embryos 1 day after fer-
tilization resulted in defects in notochord development and a
slightly shortened Anterior-Posterior axis (Fig 6C, D) with 60.4%
(n = 29 out of 48) of embryos affected after treatment with
25 nM BTZ043 and 76.7% (n = 23 out of 30) after treatment
with 50 nM BTZ043 (Fig 6G). These defects were also observed
when uninfected embryos were exposed to BTZ043. However,
no developmental defects were seen after treatment with
PBTZ169 at the same concentrations (compare Fig 4E, F) or
even at 10 lM.
Comparative efficacy of PBTZ derivatives in vivo
The in vivo efficacy of PBTZ169 and four other candidates was
assessed in the murine model of chronic TB after low-dose aerosol
infection of BALB/c mice and treatment at 50 mg/kg, the recom-
mended dose for BTZ043. Compared to the untreated control group,
the bacterial burden in the lungs and spleens of BTZ043-treated
mice was 0.6 and 1.7 logs lower, respectively (Fig 7A). All five
PBTZs were active in both organs and not inferior to BTZ043.
Strikingly, PBTZ169 and PBTZ134 reduced the bacterial burden in
the spleens 10-fold more than BTZ043 did. Furthermore, PBTZ169
had significantly greater bactericidal activity in the lungs reducing
the number of CFU by >0.5 log in comparison to BTZ043 at the
same dose (Fig 7A). This activity was also equivalent to that of








Figure 4. Treatment of M. marinum infected zebrafish embryos with
BTZ.
A One hour post infection (1 hpi) zebrafish embryos that had been
infected with 50-200 CFU of fluorescent M. marinum were treated for
5 days with BTZ043 or PBTZ169 at the concentrations indicated.
Bacterial burden was assessed by fluorescence microscopy using a Leica
MZ16FA microscope and customized software to quantify infection
levels. Graphs represent data from 2 - 8 independent experiments: ns,
not significant; **P < 0.001; ***P < 0.0001; one-way ANOVA,
Bonferronis multiple comparison test. The M strain was used for
infection.
B–F Images of infected zebrafish embryos treated with PBTZ169 at 0 (WT), 5,
25 and 50 nM, or BTZ043 at 50 nM. The arrows indicate clusters of
mycobacteria that were not present in fish treated with (P)BTZ at
concentrations >25 nM. Note that the red fluorescence on the yolk/gut
of the embryos is background staining.
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Dose escalation study and comparative pharmacokinetics
PBTZ169 was selected for further investigation and its efficacy
in vivo compared to that of BTZ043 in a dose escalation study using
the chronic model of TB. PBTZ169 was administered at 5, 10, 25, 50
and 100 mg/kg, whereas BTZ043 was given at 50 mg/kg. Four
weeks of treatment with BTZ043 reduced the bacterial burden in the
lungs and spleens by 1 log (Fig 7B). PBTZ169 was active at all the
concentrations tested and had significantly greater bactericidal activ-
ity than BTZ043 at the same dose. Lowering the dose of PBTZ169
decreased the activity, but there was no significant difference in the
bacterial burden in the lungs of mice treated with PBTZ169 at 5 mg/kg
and BTZ043 at 50 mg/kg. Above 25 mg/kg, PBTZ169 was signifi-
cantly better than BTZ043 at lowering the number of CFU in the
spleen. PBTZ169 at 25 mg/kg displayed comparable bactericidal
activity in both the lungs and spleens of mice (Fig 7B) to the front-
line drug isoniazid (INH).
To investigate whether differential exposure was responsible for
the differences observed between BTZ043 and PBTZ169 efficacy in
vivo, compound pharmacokinetics were measured in mice orally
dosed with 25 mg/kg of the respective compounds. The better effi-
cacy of PBTZ169 cannot be accounted for by differences in the phar-
macokinetics of the two compounds since, except for the faster
uptake of PBTZ169 (Supplementary Fig 4), these behaved in a simi-
lar manner (Supplementary Table 5).
Combination studies in vitro of PBTZ169 and other TB drugs
The REMA method was used to assess the viability of M. tuberculosis
H37Rv after 7 days exposure to PBTZ169 alone and in combination
Figure 5. Effect of PBTZ169 treatment on infected zebrafish embryos.
Zebrafish embryos were infected with eitherM.marinum strainM (A, B) or E11 (C,
D). Treatment with PBTZ169 (25 lM) started at 0, 1 or 2 days post-infection (dpi)
up to 5 dpi, giving exposure times of 5, 4 and 3 days, respectively. The bacterial
burden was assessed by fluorescence microscopy and customized software to
quantify the number of fluorescent pixels (A and C), and by enumeration of the
CFU in lysed embryos (B and D), immediately after imaging was performed. In B
and D, each data point represents the mean number of CFU per embryo of 3
embryo extracts plated, the bars indicate means and s.e.m. after log
transformation. The graphs represent data from 2 to 4 independent experiments.
***P < 0.0001, one-way ANOVA, Bonferroni’s multiple comparison test.
A, B Zebrafish embryos infected with M. marinum strain M.







Figure 6. Effect of BTZ043 on M. marinum infected zebrafish embryo
development.
A–D M. marinum infected zebrafish embryos were treated with BTZ043 for
5 days at the concentrations indicated and photographed using a Leica
DFC420C camera. The M strain was used for infection.
E–F Images of the notochord from untreated and treated zebrafish, arrows
indicate developmental abnormalities.
G Analysis of zebrafish embryos displaying developmental abnormalities
treated with BTZ043 (BTZ) or PBTZ169 (PBTZ) at the concentrations
indicated.
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with other approved and experimental TB drugs, as previously
described (Lechartier et al, 2012). Additive effects were seen in
combination with INH, MXF, PA-824, RIF and SQ109 but synergy
was observed when PBTZ169 was combined with BDQ (Supplemen-
tary Fig 5). The combination of PBTZ169 and BDQ gave a ΣFIC
(sum of the fractional inhibitory concentrations) of 0.5 using the
checkerboard method indicating that the drugs act synergistically to
inhibit growth of M. tuberculosis (Supplementary Fig 5). To confirm
the bactericidal effect of this combination the number of CFU was
determined after 7 days’ exposure. The data show that the combina-
tion of 0.125 ng/ml of PBTZ169 and 25 ng/ml BDQ, which both
have little or no impact on bacterial growth when used alone, show
clear bactericidal activity when used in combination thereby
confirming their synergistic interaction (Fig 8).
Combination studies in the mouse model of chronic TB
If PBTZ169 is to be used in a new regimen for TB treatment in
humans it is important to demonstrate the efficacy of appropriate
drug combinations in animal models. Consequently, we assessed
the combination found to be synergistic in vitro in the murine model
of chronic TB after low-dose aerosol infection. PBTZ169 was tested
alone (at 25 mg/kg), in combination with BDQ (25 mg/kg) and
pyrazinamide (PZA; 150 mg/kg), and with both drugs together,
against M. tuberculosis H37Rv. The reduction in the bacterial bur-
den in the lungs and spleens was measured after 4 and 8 weeks of
treatment and compared to that obtained with the standard three
drug therapy comprising INH, RIF and PZA at concentrations of
25, 10 and 150 mg/kg, respectively. As can be seen in Fig 9, the
combination of PBTZ169 and BDQ was more effective than the
standard treatment in reducing the number of CFU in both organs
after 1 month of treatment (P values = 0.004 for the lung, 0.002
for the spleen) whereas the addition of PZA did not further
improve the potency of the combination at this stage (P = 0.003
for the spleen). The number of bacteria remaining in the lungs of
mice treated with the experimental combination was below the
limit of detection used at this time-point (<200 CFU). After
2 months of treatment (Fig 9), only the triple combination PBTZ,
BDQ and PZA was significantly better than RHZ both in the lungs
(P = 0.046) and in the spleen (P = 0.015; Supplementary Table 6).
The efficacy of the combination of PBTZ, BDQ and PZA was thus
superior to the standard triple therapy INH, RIF and PZA in the
chronic model of TB.
Discussion
Our goal was to use structure-activity-relationship (SAR) studies of
BTZ to produce a preclinical candidate for subsequent use as a TB
drug in humans. The addition of a piperazine to the BTZ scaffold
resulted in even more potent derivatives, the PBTZ series that can
also be formulated as salts. PBTZ169 proved to be the most suitable
candidate for development and this was intensively investigated
alongside the first generation lead, BTZ043. While the mechanism
of action of both compounds was identical, inhibition of DprE1
function by formation of a covalent bond to the active site cysteine
residue, PBTZ169 has many superior features.
First, there are no chiral centers in the compound so the synthe-
sis, quality control and, above all, manufacturing will be less expen-
sive, an important factor for a disease that mainly concerns the
developing world. Second, PBTZ169 is less cytotoxic than BTZ043
and showed significantly better efficacy at lower concentrations in
the murine model of chronic TB (Fig 7) and this may be attributed
to the fact that PBTZ169 inhibits DprE1 more efficiently than
BTZ043 does. There was a notable reduction in bacterial loads in
the lungs and, especially, the spleen following treatment with
PBTZ169 and PBTZ134, compared to BTZ043 treatment, and these
two drug candidates are as potent as INH. Third, the better protec-
tion of PBTZ169 from nitroreductases (Fig 2) may eventually be
important as other microorganisms (e.g. in the human digestive
A
B
Figure 7. Efficacy studies in vivo.
A Efficacy of 5 PBTZ candidates in a mouse model of chronic TB compared
with INH (25 mg/kg), BTZ043 and untreated controls (NT). All BTZs were
administered at 50 mg/kg of body weight per day. Red and black columns
correspond to the bacterial burden in the lungs and spleens, respectively,
at day 0 (D0) when treatment initiated, or day 28 (D28) when treatment
finished. Bars represent the mean  s.d. of CFUs from 5 mice per group.
Significance in difference relative to BTZ043 were calculated using
Students t-test. *P < 0.05; **P < 0.005.
B Dose escalation study of PBTZ169 in the same model. 5 mice per group
were treated with various drugs at the doses indicated (mg/kg). Colors,
bars and statistics are as in (A).
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tract) or host enzymes could also reduce benzothiazinones to their
inactive hydroxylamino or amino forms.
Differences in pharmacokinetics cannot account for the superior
behavior of PBTZ169 (Supplementary Fig 4) as both compounds dis-
played similar properties. Pharmacokinetic studies showed that
PBTZ169 appears to be absorbed more rapidly than BTZ043 with
absorption likely occurring in the stomach as well as in the intes-
tines. The better solubility of PBTZ169 in acidic conditions may
account for this. Furthermore, from the exposure profile of PBTZ169
in mice it appears that once daily dosing should be sufficient in
humans as the serum level remains well above MIC for >21 h.
From an SAR standpoint, the availability of co-crystal structures
of DprE1 with both BTZ043 (Neres et al, 2012) and PBTZ169 also
helps our understanding. The M. tuberculosis DprE1 structure with
PBTZ169 shows that binding of this benzothiazinone is in full agree-
ment with the previously reported M. smegmatis DprE1 in complex
with BTZ043 (Neres et al, 2012). The benzothiazinone rings of
BTZ043 and PBTZ169 adopt identical positions in the active site of
DprE1. The greater flexibility of the cyclohexylmethyl-piperazine
moiety of PBTZ169, making it more adaptable to the active site
when compared to BTZ043, might account in part for its higher
affinity and faster inactivation of DprE1. In addition, the likely pro-
tonation of one of the piperazine ring nitrogen atoms of PBTZ169
could generate a favourable interaction with two negatively charged
residues, namely Asp318 and Glu322, present in the disordered loop
(residues 314-328) located over the active site. Information obtained
here about the localization of FPX in the DprE1 active site will also
facilitate understanding of the enzymatic reaction and aid rational
drug design.
Another potentially important difference between PBTZ169 and
BTZ043 was detected through use of the zebrafish embryo model fol-
lowing infection with M. marinum. Although both compounds low-
ered the bacterial burden in a dose-dependent manner, exposure to
BTZ043 seemingly led to developmental abnormalities (Fig 6). These
included the appearance of deposits in the notochord and the subse-
quent shortening of the Anterior-Posterior axis resulting in shorter
body length although the reason for this is unknown. When PBTZ169
was tested in this model no such developmental defects were observed
making this the preferred compound for clinical development.
Of considerable significance with respect to the ultimate objec-
tive of curing disease in humans was the full compatibility of
PBTZ169, and BTZ043 (Lechartier et al, 2012), with all the other
approved and experimental TB drugs tested. The synergy between
PBTZ169 and BDQ was particularly noteworthy and may be
explained in two possible ways; weakening of the cell wall by DprE1
inhibition leading to better penetration of BDQ and easier access to
its target, ATP synthase. Alternatively, loss of DprE1 activity, due to
binding of PBTZ169, might result in fewer reducing equivalents
entering the electron transfer chain from FADH2.
Full compatibility with other drug candidates means that novel
combinations including PBTZ169 can be readily assembled and this
Figure 8. Synergistic interaction in vitro between BDQ and
PBTZ169. The effect of serial dilutions of PBTZ169 and BDQ in combination on
the viability of M. tuberculosis H37Rv was assessed after 7 days exposure.
Bacterial dilutions were plated on solid medium and incubated for 1 month
before counting the number of CFU. Drug concentrations are in ng/ml.
Figure 9. Efficacy of PBTZ169-based combination treatment inmice. The
bactericidal effects of PBTZ, BDQ (both 25 mg/kg) and PZA (150 mg/kg) alone and
in combination were compared in the lung (A) and in the spleen (B) with a
standard regimen of RIF, INH and PZA (RHZ) and untreated controls (NT) in the
murinemodel of chronic TB. The combination of PBTZ169 and BDQ plus PZA was
significantly more effective than the standard treatment in reducing the number
of CFU in both organs after 1 and 2 months of treatment (Supplementary Table
6). The lung CFU count of PBTZ-BDQ-PZA (*) was below the limit of detection
used after 4 weeks of treatment (<200 CFU).
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is consistent with the current thinking that it may be more efficient
and less time-consuming to test new regimens in clinical trials rather
than testing a series of single drugs separately (Diacon et al, 2012).
Highly encouraging results were obtained against chronic murine TB
when PBTZ169 was combined with BDQ or PZA or both drugs (Fig 9)
as these combinations reduced the bacterial load more rapidly than
the current tri-therapy (RIF, INH, PZA). It is now urgent to complete
the preclinical development of PBTZ169, since it is an attractive,
well-understood drug candidate that offers great potential not only
for the control of TB but also for other mycobacterial diseases, such
as leprosy and Buruli ulcer, as well as for related infections like
Nocardiosis (Makarov et al, 2006; Vera-Cabrera et al, 2012).
Materials and Methods
Chemistry
Standard procedures were applied and the synthetic route for PBTZ
compounds is described in the supporting information (Makarov
et al, 2006; Makarov, 2011). All compounds were at least 96% pure.
Bacterial strains and culture conditions
Bacterial strains, BTZ-resistant mycobacterial mutants and M. tuber-
culosis strain H37Rv were grown at 37°C with shaking in Middle-
brook 7H9 (Difco) broth supplemented with 10% albumin-dextrose-
catalase (ADC) enrichment, 0.2% glycerol, 0.05% Tween 80. The
M. marinum strains E11 (Puttinaowarat et al, 2000) and M ((Stinear
et al, 2008)ATCC BAA-535) containing the plasmid pSMT3-mcherry
(Meijer et al, 2008) to visualize bacteria, were routinely grown at
30°C in Middlebrook 7H9 broth (Difco) with 10% Middlebrook albu-
min-dextrose-catalase (ADC, BD Bioscience) and 0.05% Tween-80
by shaking at 90 rpm or on Middlebrook 7H10 agar (Difco) supple-
mented with 10% oleic acid-albumin-dextrose-catalase (OADC, BD
Bioscience) and 50 mg/ml hygromycin.
Antimicrobials
Drugs were purchased from Sigma or provided by Tibotec (BDQ).
PBTZ derivatives were suspended in 0.5% carboxymethyl cellulose
for the comparative efficacy studies. PBTZ169 and BDQ were sus-
pended in 20% hydroxypropyl-b-cyclodextrin (pH = 3.0) for in vivo
combination studies. Solutions of compounds for administration to
mice were prepared weekly and stored at 4°C for all compounds but
BDQ which was prepared monthly and stored at 4°C. PZA, INH, and
RIF were suspended in water.
Biochemistry and structural biology
NfnB assays were performed at 25°C, as outlined previously (Manin-
a et al, 2010). Briefly, compounds were added to a reaction mixture
containing NfnB (6 lM), NADH (150 lM), 50 mM Tris-HCl pH 8.0,
150 mM NaCl, and 5% glycerol. Full details of the purification and
crystallization of M. tuberculosis DprE1 are given in the supporting
information. DprE1 inhibition was assessed following incubation
with BTZ043 or PBTZ169 (0–20 lM) for 5 min, using a peroxidase-
coupled assay with Amplex Red as a substrate. The enzyme (5 lM)
was incubated at 30°C with inhibitor and 200 lM FPR, in 50 mM
glycylglycine pH 8.4, 100 mM NaCl. An aliquot (5 lL) was taken
after 5 min incubation and diluted assay mixture (final volume
50 lL) to give final concentrations of 400 lM FPR, 0.2 lM horserad-
ish peroxidase and 50 lM Amplex Red and 0.5 lM DprE1. The per-
oxidase activity was then assessed by continuous measurement of
the fluorescence with excitation/emission wavelengths of 560/
590 nm, respectively. Analysis of DprE1-PBTZ169 complexes by
mass spectrometry was performed as reported previously, now
using M. tuberculosis DprE1 (Neres et al, 2012).
Zebrafish infection
The zebrafish (Danio rerio) embryo infection experiments were per-
formed largely as described previously (Stoop et al, 2011). Volumes
of 1 nl of bacterial suspension, containing 50-200 CFU were injected
into the caudal vein of embryonic zebrafish at approximately 28 h
post fertilization. At 5 days post infection, embryos were monitored
using fluorescence microscopy (Leica MZ16FA). Brightfield and
fluorescent images were generated with a Leica DFC420C camera
and subsequently fluorescent images were analyzed with custom-
ized software to quantify infection levels. An updated version of the
previously described software was used (see http://bio-imaging.
liacs.nl/galleries/granulomaload/).
Zebrafish drug treatment
Twelve infected embryos were incubated at 28°C in petri dishes of
4 cm diameter containing 4 ml sterilized egg water (60 lg/ml
instant ocean sea salts) with 0.003% 1-phenyl-2-thiourea (Sigma) to
prevent melanization. All drug treatment experiments were per-
formed in egg water containing 1% DMSO and analyzed at 5 days
post infection (dpi). Compound concentrations were tested at least
three times. Compounds were administered once to the egg water
either at 1 h post infection (hpi), 1 day post infection (dpi) or 2 dpi.
The embryos remained in the same 4 ml egg water for the duration
of the experiments, no daily refreshments of the egg water nor addi-
tions of more compound were performed. All procedures involving
zebrafish embryos were executed in compliance with local animal
welfare laws.
Determination of bacterial loads of infected zebrafish embryos
Embryo lysates were prepared as described previously (Stoop et al,
2011). Briefly, pools of three embryos were dissociated in the
presence of 5% (w/v) SDS, lysed and decontaminated by incubation
with MycoPrep reagent (BD Bioscience), neutralized with phosphate
buffered saline (PBS) then serial dilutions were plated.
Murine infection models, treatment and assessment of efficacy
Female BALB/c mice, aged 5–6 weeks, were obtained from Charles
River Laboratories. The in vivo efficacy of single drugs and combina-
tions was assessed 4 weeks after a low-dose aerosol infection of
mice in the chronic model of TB, by gavage 5 days a week for
4 weeks. Experiments were approved by the Swiss Cantonal Veteri-
nary Authority (authorization no. 2218).
Drug treatment began 4 weeks after infection at the following
doses (mg/kg): BDQ, 25; PBTZ, 25; PZA, 150; RIF, 10; INH, 25.
Control and treated mice were sacrificed, the lungs and spleens
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homogenized, and dilutions plated on 7H10 agar enriched with 10%
OADC and supplemented with cycloheximide (10 lg/ml), ampicillin
(85 lg/ml) and 0.4% w/v of activated charcoal (Sigma) to prevent
compound carry-over. The plates were incubated for 35 days at 37°C
before CFU were enumerated. CFU counts were log10 transformed
before analysis as mean log10 CFU  s.d., and compared using Stu-
dent’s t tests in Prism version 5.0 (Graphpad).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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pounded by widespread resistance to both frontline and second-line
drugs due to infection with multidrug- and extensively drug-resistant
strains of Mycobacterium tuberculosis, respectively. As a direct conse-
quence of these failings there is a great need to discover and to
develop new drugs and drug combinations.
Results
Here, we disclose the next generation of benzothiazinone compounds
and present an optimized preclinical candidate, PBTZ169, that is
highly potent against drug-susceptible and drug-resistant Mycobacte-
rium tuberculosis. Like other benzothiazinones, PBTZ169 acts by form-
ing a covalent bond to an active site cysteine residue in an enzyme
essential for the production of the mycobacterial cell wall. The three-
dimensional structure of PBTZ169 in complex with its target has been
solved and used to explain the action of this drug candidate. More
importantly, PBTZ169 was shown to be most effective at treating
tuberculosis in two different animal models and to be compatible
with both existing and experimental tuberculosis drugs.
Impact
In this work we present an advanced preclinical candidate drug for
the treatment of tuberculosis in humans. PBTZ169 has been exten-
sively characterized in terms of its chemical, biochemical, microbio-
logical and pharmacokinetic properties. Of capital importance is the
synergistic behaviour of PBTZ169 and bedaquiline, a drug recently
approved for the treatment of multidrug-resistant tuberculosis, and
with the classical drug pyrazinamide. The available data suggest that
a combination of these three molecules should be highly efficacious
in treating all forms of tuberculosis in humans.
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